Table 2 Subgroup analysis for overall survival
From: Prognostic value of consolidation-to-tumor ratio on computed tomography in NSCLC: a meta-analysis
| Â | Number of studies | HR | 95% CI | P value | Heterogeneity (P, I2 (%)) |
|---|---|---|---|---|---|
Overall survival | 21 | 1.88 | 1.42–2.50 |  < 0.01 | 0.013, 45.4 |
Country | |||||
 China | 6 | 1.81 | 1.35–2.44 |  < 0.01 | 0.172, 35.3 |
 Japan | 13 | 2.37 | 1.59–3.53 |  < 0.01 | 0.222, 21.9 |
 Korea | 1 | 3.33 | 0.38–29.33 | 0.278 | –, – |
 Turkey | 1 | 0.44 | 0.19–0.97 | 0.043 | –, – |
Cut-off value | |||||
 0.25 | 1 | 3.33 | 0.38–29.33 | 0.278 | –, – |
 0.5 | 11 | 1.79 | 1.03–3.11 | 0.039 | 0.022, 52.0 |
 0.75 | 3 | 2.52 | 1.65–3.83 |  < 0.01 | 0.335,8.5 |
 0.8 | 1 | 6.20 | 0.80–47.83 | 0.080 | –, – |
 0.85 | 1 | 1.44 | 0.12–17.49 | 0.775 | –, – |
 Continuous variable | 4 | 1.69 | 1.06–2.72 | 0.027 | 0.056,60.3 |
Source of HR | |||||
 Reported | 14 | 1.98 | 1.46–2.68 |  < 0.01 | 0.114, 32.6 |
 Estimated | 7 | 1.70 | 0.86–3.37 | 0.126 | 0.010, 64.6 |
Histology type | |||||
 Adenocarcinoma | 13 | 1.68 | 1.10–2.56 | 0.016 | 0.004,59.0 |
 NSCLC | 8 | 1.88 | 1.41–2.51 |  < 0.01 | 0.400,3.9 |